Sonoma Biotherapeutics
PrivateLast Round
Strategic
Mar 28, 2023
Total Funding Raised
$365M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Sonoma Biotherapeutics operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Strategic round in March 2023.
Sonoma Biotherapeutics is a biotechnology company that develops engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sonoma Biotherapeutics Comparables
Compare Sonoma Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GentiBio | 86% | |
| Quell Therapeutics | 84% | |
| Tr1X | 84% |
For institutional investors. Book with your work email.
Sonoma Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Mar 28, 2023 | ||||
| Series B | Aug 4, 2021 | ||||
| Series A Extension | Sep 30, 2020 | ||||
| Series A | Feb 6, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sonoma Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| Frazier Healthcare Partners | Series B |
| Vertex Ventures HC | Series B |
| GV | Series B |
| Mirae Asset | Series B |
| Octagon Capital Advisors | Series B, Series A Extension |
| Ally Bridge Group | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 32% MoM, reaching 7.5K.
- Jul 29, 2026
Monthly visitors increased 58% MoM, reaching 5.7K.
For institutional investors. Book with your work email.
Sonoma Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sonoma Biotherapeutics's valuation, stock price, and market status.
Is Sonoma Biotherapeutics a public or private company?
Sonoma Biotherapeutics is a private company.
What is the current stock price of Sonoma Biotherapeutics?
Sonoma Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Sonoma Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sonoma Biotherapeutics worth (valuation)?
Valuation information for Sonoma Biotherapeutics is not publicly available.
Can I buy Sonoma Biotherapeutics stock?
Sonoma Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sonoma Biotherapeutics's last funding round?
Sonoma Biotherapeutics's most recent funding round was Strategic on March 28, 2023.
Who are the main investors in Sonoma Biotherapeutics?
Key investors in Sonoma Biotherapeutics include Ally Bridge Group, Lifeforce Capital, ARCH Venture Partners.
Will Sonoma Biotherapeutics IPO soon?
No public IPO plans have been announced for Sonoma Biotherapeutics.
How can I track Sonoma Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Sonoma Biotherapeutics's shares on secondary markets.